Commercial-stage biopharmaceutical company InnoCare Pharma (HKEX:09969) (SSE:688428) announced on Tuesday that it has received US Food and Drug Administration (FDA) clearance for a clinical trial of its TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, for treating moderate-to-severe atopic dermatitis (AD).
ICP-332 demonstrated positive results in a prior China Phase II study, showing better efficacy than other AD treatments. The drug targets the JAK-STAT signalling pathway, crucial in AD development.
At present, no TYK2 inhibitors have obtained marketing approval for the treatment of AD anywhere in the world.
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Psilera collaborates with Hesperos for PSIL-006 preclinical modelling for frontotemporal dementia
Myosin Therapeutics' MT-125 cleared by US FDA to initiate first-in-human trial in glioblastoma
Ondine's Steriwave proven effective against deadly Mucor fungus
AB Science receives EMA approval to extend Masivet shelf life to four years
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
NRx Pharmaceuticals files ANDA for preservative-free IV ketamine
Innovent's IBI363 granted second breakthrough therapy designation in China
Implantica reports positive NICE guidance for RefluxStop procedure in UK hospitals